SCHEDULE: Baker Bros. Secure Incyte Resale Rights

Baker Bros. Advisors and affiliated funds have entered into a registration rights agreement with Incyte Corp, allowing for future resale of their significant stake.

Summary

• Baker Bros. Advisors and its affiliates, including Julian C. Baker and Felix J. Baker, collectively beneficially own approximately 15.7% of Incyte Corp's common stock.
• This ownership includes 31,213,417 shares for Felix J. Baker and 31,211,000 shares for Julian C. Baker.
• The beneficial ownership percentages are based on 199,014,486 shares of Common Stock outstanding as of February 3, 2026.
• On February 6, 2026, Baker Brothers Life Sciences, L.P. and 667, L.P. (the "Funds") entered into a Registration Rights Agreement with Incyte Corp.
• This agreement grants the Funds certain resale registration rights for all their Incyte securities, including equity, debt, and common stock issuable upon exercise or conversion.
• Incyte is obligated to file a resale registration statement (Form S-3) upon the Funds' request and maintain its effectiveness.
• The Funds are entitled to one underwritten public offering per calendar year, with a maximum of three total, and no more than two underwritten public offerings or block trades in any twelve-month period.
• These registration rights will remain in effect for up to ten years.
• Julian C. Baker's director compensation (Stock Options, RSUs, Common Stock) has its pecuniary interest assigned to the Funds, with the Adviser retaining voting and investment power.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive for the reporting persons as it formalizes a clear exit strategy for their significant stake, providing liquidity options. For the issuer, it's neutral to slightly negative due to potential future share overhang.

Positives

• The Registration Rights Agreement provides the Funds with a clear and structured mechanism to monetize their significant investment in Incyte Corp, enhancing liquidity options.
• The ability to conduct underwritten public offerings or block trades offers flexibility for large-scale share dispositions without negatively impacting market price as much as open market sales.

Negatives

• The filing does not explicitly state any negative aspects. However, the potential for large share sales by a major holder could create overhang on the stock.

Risks

• The existence of a Registration Rights Agreement for a significant shareholder group (15.7% of outstanding shares) introduces the potential for future large-scale sales of Incyte Corp common stock.
• Such sales, if executed, could increase the supply of shares in the market, potentially exerting downward pressure on the stock price.

Future Outlook

The Registration Rights Agreement provides a framework for the Funds to potentially sell their Incyte shares over the next ten years, indicating a long-term strategy for managing their investment.

Management Comments

• "The Funds' respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds' investments and voting power over investments."
• "The policy of the Funds and the Adviser does not permit managing members of the Adviser GP or full-time employees of the Adviser to receive compensation for serving as a director of the Issuer. Therefore, Julian C. Baker has no pecuniary interest in the Stock Options, Common Stock, RSUs or Common Stock received as directors' compensation. The Funds are instead entitled to the pecuniary interest."

Industry Context

StockSavvy.ai notes that large institutional investors frequently seek registration rights agreements when holding significant stakes in public companies. This allows them to manage their positions efficiently, especially in the biotechnology sector where investment horizons can be long and liquidity needs may arise for portfolio rebalancing or fund distributions. This move by Baker Bros., a prominent life sciences investor, is a standard practice for managing a substantial, long-term investment.

Comparison to Industry Standards

• The terms of the Registration Rights Agreement, including the ability to request S-3 filings and conduct underwritten offerings, are standard for significant institutional investors seeking liquidity for large blocks of shares.
• Similar agreements are often seen with venture capital or private equity firms exiting investments in biotech companies like Moderna or BioNTech after IPOs, or with activist investors in companies such as Sarepta Therapeutics or Vertex Pharmaceuticals.
• The limits on the number of offerings (one per year, three total, two per 12 months) are typical to balance the investor's need for liquidity with the issuer's desire to avoid excessive market disruption.

Corporate Governance

Related Party Transactions

• Julian C. Baker, a director of Incyte Corp and a managing member of the Adviser GP, receives Stock Options, RSUs, and Common Stock as director's compensation.
• The pecuniary interest in this compensation is assigned to the Funds, not Julian C. Baker personally, due to the policy of the Funds and the Adviser.
• The Adviser has voting and investment power over this compensation.

Stakeholder Impact

• Shareholders: The Registration Rights Agreement could lead to future sales of a significant block of shares, potentially increasing market supply and influencing share price. It also provides transparency regarding a major investor's exit strategy.
• Funds (Baker Bros. Life Sciences, L.P. and 667, L.P.): The agreement provides a structured and efficient mechanism to monetize their investment in Incyte Corp, enhancing their ability to manage portfolio liquidity and distributions.
• Incyte Corp: The company is obligated to facilitate the registration and potential sale of shares by a major investor, which could involve administrative effort and potential market perception impacts.

Next Steps

• Incyte Corp is obligated to file a resale registration statement (Form S-3) upon request from the Funds.
• The Funds may request underwritten public offerings or block trades of their Registrable Securities, subject to specified limits, over the next ten years.

Key Dates

Recommendation

While the filing indicates a major institutional investor has formalized a mechanism to potentially exit their position over time, it does not signal an immediate sell-off or a change in the underlying fundamentals of Incyte Corp. The registration rights provide liquidity options for Baker Bros. but do not inherently suggest a negative outlook on the company. Investors should hold and monitor any actual sales activity and Incyte's operational performance.

Keywords

Incyte Corp, Baker Bros. Advisors, Schedule 13D, Beneficial Ownership, Registration Rights Agreement, Form S-3, Underwritten Offering, Block Trade, Institutional Investor, Biotechnology, Pharmaceuticals